Harmony Biosciences Q2 revenue $200.5M (+16% YoY); EPS $0.68; reaffirms FY guidance $820-860M

Harmony Biosciences Holdings, Inc.

2025-Q2 EPS reported $1.46 revenue$385,222,000

Net product revenue $200.5M (+16% YoY); GAAP net income $39.8M ($0.68 diluted EPS); non-GAAP adj. net income $53.8M ($0.92 diluted EPS).
Reaffirms 2025 revenue guidance $820M-$860M; added 400 average patients to 7,600 in Q2.
Phase 3 ZYN002 topline data in Fragile X syndrome on track for Q3 2025; targets ~80K U.S. patients.
Entered research collaboration with CiRC Biosciences for refractory epilepsy & narcolepsy; $15M upfront paid.
Settled ANDA litigation with Lupin; generic launch no earlier than Jan 2030 (or July 2030 with pediatric exclusivity).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.